Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $31.53 in the prior trading day, Procept BioRobotics Corp (NASDAQ: PRCT) closed at $31.46, down -0.22%. In other words, the price has decreased by -$0.22 from its previous closing price. On the day, 1.01 million shares were traded. PRCT stock price reached its highest trading level at $31.51 during the session, while it also had its lowest trading level at $31.0.
Ratios:
Our goal is to gain a better understanding of PRCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.19 and its Current Ratio is at 8.43. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In the most recent recommendation for this company, UBS on December 12, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
On December 08, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $38.
Oppenheimer Upgraded its Perform to Outperform on September 02, 2025, while the target price for the stock was maintained at $60.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when MOLL FREDERIC H bought 20,000 shares for $39.26 per share. The transaction valued at 785,138 led to the insider holds 863,159 shares of the business.
Desai Antal Rohit sold 25,000 shares of PRCT for $1,597,711 on Jun 10 ’25. The Director now owns 64,363 shares after completing the transaction at $63.91 per share. On Jun 11 ’25, another insider, Desai Antal Rohit, who serves as the Director of the company, sold 25,000 shares for $63.38 each. As a result, the insider received 1,584,525 and left with 39,363 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 1757940352 and an Enterprise Value of 1542585472. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.86 while its Price-to-Book (P/B) ratio in mrq is 4.62. Its current Enterprise Value per Revenue stands at 5.144 whereas that against EBITDA is -17.855.
Stock Price History:
The Beta on a monthly basis for PRCT is 0.99, which has changed by -0.626809 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, PRCT has reached a high of $89.49, while it has fallen to a 52-week low of $27.80. The 50-Day Moving Average of the stock is -4.21%, while the 200-Day Moving Average is calculated to be -31.21%.
Shares Statistics:
The stock has traded on average 1.43M shares per day over the past 3-months and 1077770 shares per day over the last 10 days, according to various share statistics. A total of 55.87M shares are outstanding, with a floating share count of 53.76M. Insiders hold about 3.79% of the company’s shares, while institutions hold 104.10% stake in the company. Shares short for PRCT as of 1765756800 were 6081396 with a Short Ratio of 4.26, compared to 1763078400 on 6784186. Therefore, it implies a Short% of Shares Outstanding of 6081396 and a Short% of Float of 12.889999999999999.
Earnings Estimates
The market rating of Procept BioRobotics Corp (PRCT) is currently shaped by the ongoing analysis conducted by 9.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.11 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.47 and -$1.54 for the fiscal current year, implying an average EPS of -$1.51. EPS for the following year is -$1.09, with 9.0 analysts recommending between -$0.52 and -$1.32.
Revenue Estimates
12 analysts predict $93.7M in revenue for. The current quarter. It ranges from a high estimate of $94.11M to a low estimate of $92.8M. As of. The current estimate, Procept BioRobotics Corp’s year-ago sales were $68.24MFor the next quarter, 12 analysts are estimating revenue of $92.2M. There is a high estimate of $94.64M for the next quarter, whereas the lowest estimate is $88.82M.
A total of 13 analysts have provided revenue estimates for PRCT’s current fiscal year. The highest revenue estimate was $338.51M, while the lowest revenue estimate was $324.47M, resulting in an average revenue estimate of $326.38M. In the same quarter a year ago, actual revenue was $224.5MBased on 13 analysts’ estimates, the company’s revenue will be $421.74M in the next fiscal year. The high estimate is $433.03M and the low estimate is $414.8M.
